CHIMERA INVESTMENT CORP - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Chimera Investment Corporation on September 10, 2025, covering events occurring on September 9, 2025. The Company is a Maryland corporation with principal executive offices in New York, New York. It is not an emerging growth company.
Key Financial Metrics and Capital Structure
The filing details a new debt issuance rather than reporting operational financial results such as revenue or cash flow for a specific period.
- New Debt Issuance: $115 million aggregate principal amount of 8.875% Senior Notes due 2030.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional $17.25 million of the Notes.
- Closing Date: Scheduled for September 16, 2025.
- Existing Securities: The Company has multiple classes of preferred stock (Series A, B, C, D) and senior notes (due 2029) registered on the New York Stock Exchange.
The filing text does not provide clear values for current revenue, profit, operating cash flow, margins, or total existing debt levels.
Material Changes
The primary material change is the entry into a definitive underwriting agreement to raise capital through the issuance of the new Senior Notes. This increases the Company's outstanding debt obligations upon closing.
Outlook, Risks, and Management Commentary
The Company entered into an underwriting agreement with Morgan Stanley & Co. LLC, RBC Capital Markets, LLC, UBS Securities LLC, Wells Fargo Securities, LLC, Keefe, Bruyette & Woods, Inc., and Piper Sandler & Co. The offering is subject to customary closing conditions. The Company agreed to indemnify the underwriters against certain liabilities. No specific forward-looking guidance or risk factors beyond standard underwriting terms are detailed in this specific filing text.
Key Facts for Investor Verification
- Verify the final closing of the $115 million 8.875% Senior Notes due 2030 on September 16, 2025.
- Confirm whether the underwriters exercised the $17.25 million over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and use of proceeds.
- Assess the impact of the new 8.875% interest rate on the Company's overall cost of debt and leverage ratios.